Roman Crazzolara

Dr. Roman Crazzolara


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2022 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
AMAndreas Meryk
Andreas Meryk
GKGabriele Kropshofer
Gabriele Kropshofer
BHBenjamin Hetzer
Benjamin Hetzer
DRDavid Riedl
David Riedl
JLJens Lehmann
Jens Lehmann
RCRoman Crazzolara
Roman Crazzolara
Digital health care is a broad concept that includes the use of diverse technologies for mobile health, health information, and wearable devices to quantify the mental and physical condition of the user. One example of this concept is the use of patient-reported outcome measurements (PROMs) for supportive care among adults with cancer.1,2 When PROMs are recorded, subjective impairments caused by the disease and its treatment are identified early and medical interventions are initiated, which results in improved overall survival and health-related quality of life.1-5 Although the use of PROMs in clinical cancer research has repeatedly been encouraged by regulatory agencies, implementation has primarily been restricted to adult patients. In fact, less than 1% of pediatric clinical trials submitted to ClinicalTrials.gov and EudraCT (European Union Drug Regulating Authorities Clinical Trials) use PROMs as a primary end point.6,7 Several shortfalls in pediatrics may be explained in part by (1) insecurity regarding the choice of the appropriate PROM questionnaire, (2) skepticism regarding PROM data collection, (3) inappropriate timing of assessment, and (4) inadequate statistical analysis and outcome interpretation.8 The biggest hurdle to overcome in pediatrics, however, is the fact that the professional team needs to interact not only with the children, but also with their proxies. Although some PROMs offer promise in routine clinical care of pediatric patients with cancer,9-11 no study to our knowledge has evaluated daily PROMs on a long-term basis or differentiated between surveys administered in the hospital or at home.

12 August 2021 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
PDF file
AMAndreas Meryk
Andreas Meryk
GKGabriele Kropshofer
Gabriele Kropshofer
BHBenjamin Hetzer
Benjamin Hetzer
DRDavid Riedl
David Riedl
JLJens Lehmann
Jens Lehmann
RCRoman Crazzolara
Roman Crazzolara
Background: Several stakeholders, including patients and health care providers, suggest symptom self‐reporting measurements for a more patient‐directed cancer control approach. However, services tailored to measure daily reporting and implementing it in clinical care are lacking. This study aimed to evaluate the feasibility and value of daily patient‐reported outcome measures (PROMs) by children receiving chemotherapy for cancer.Methods: Health status was recorded daily with a web‐based child‐friendly patient portal (ePROtect). Following aspects of feasibility and usability were assessed: (a) the completion rate and time, (b) user feedback on usability and satisfaction, and (c) the performed interventions if moderate to severe symptom deterioration was noted.Results: Twelve children (median age: 7.2 years) were included. A total number of 891 daily reports were collected during the study period; the median percentage of ePROtect completion days was 85.3% (interquartile range [IQR] 64.2–100.0) and 55.9% (IQR 51.9–76.9) for inpatient and outpatient stay, respectively. Mean time to complete the questionnaire was 47.6 seconds. Severe symptoms were reported in 14.7% of measurement time points, which led to prompt health care interventions in 57 cases, including extension of supportive care (n = 37) and pre‐emptive inpatient admissions (n = 5). Over 80% of the patients (10/12) and their proxies (16/18) provided feedback with high rating for satisfaction (>90%) and usefulness (>80%) of ePROtect.Conclusion: Our study shows that daily symptom monitoring is feasible for all children with newly diagnosed cancer aged 5–18 years. Monitoring offers the opportunity to identify symptoms early and trigger appropriate clinical action.

8 April 2015 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
RCRoman Crazzolara
Roman Crazzolara
KMKathrin Maurer
Kathrin Maurer
HSHarald Schulze
Harald Schulze
BZBarbara Zieger
Barbara Zieger
JZJozef Zustin
Jozef Zustin
ASAnsgar S. Schulz
Ansgar S. Schulz

1 February 2009 in Current Cancer Drug Targets
Verified
Journal Article
Closed access
PDF file
RCRoman Crazzolara
Roman Crazzolara
LBL. Bendall
L. Bendall
Abstract: Acute lymphoblastic leukemia (ALL) is a clonal proliferation of early B- and T-lymphocyte progenitors and results in the accumulation of leukemic blasts in the bone marrow and various extramedullary sites. It affects both children and adults, with peak prevalence between the ages of 2 to 5 years. Despite current treatment protocols achieving rapid cytoreduction in the vast majority of patients, serious acute and late complications are frequent and resistance to chemotherapy often develops. In contrast to the successes obtained with pediatric patients, treatment outcomes for adults remain poor with only 40% of patients being long-term survivors. Extensive research in the field of ALL has helped understand the mechanisms that control leukemic cells, facilitating the design of new drugs that specifically interfere with leukemic pathways and overcome chemo-resistance induced by common treatment regimens. Herein, we review the current status of the development of novel anti-leukemic agents, with emphasis on small molecular inhibitors that have already translated into clinical trials and are in the advanced stages of preclinical development. Challenges to successful development of each strategy are discussed.

21 July 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
APAlexandra Podpeskar
Alexandra Podpeskar
RCRoman Crazzolara
Roman Crazzolara
GKGabriele Kropshofer
Gabriele Kropshofer
BHBenjamin Hetzer
Benjamin Hetzer
EREvelyn Rabensteiner
Evelyn Rabensteiner
CSChristina Salvador
Christina Salvador
Background: As one of the few modifiable risk factors, the importance of dietary patterns for both disease prevention and treatment outcome in pediatric oncology has gained increasing popularity. Malnutrition is associated with lower survival rates, tolerance to treatment, and quality of life. Yet, especially in children with malignancies, nutritional deterioration is common, and pediatric cancer patients often present with inadequate intake of micro- and macronutrients alike. Despite the reported widespread use of dietary supplements, few empirical data provide a basis for clinical recommendations, and evidence for their efficacy is inconsistent. Current literature lacks a systematic approach as to how and which supplements should be recommended for specific patients, types of cancer, or during specific treatments. The aim of this review is to highlight the role of the most frequently used nutrients in pediatric malignant diseases and to give a practical guide based on current scientific evidence. Methods: A comprehensive literature search was conducted on PubMed through April 2023 to select meta-analyses, systematic reviews, observational studies, and individual randomized controlled trials (RCTs) of macro- and micronutrient supplementation in pediatric oncology. The search strategy included the following medical subject headings (MeSH) and keywords: “childhood cancer”, “pediatric oncology”, “nutritional status”, “dietary supplements”, “vitamins”, “micronutrients”, “calcium”, “magnesium”, “vitamin D”, “zinc” “glutamine”, “selen”, and “omega-3 fatty acids”. The reference lists of all relevant articles were screened to include potentially pertinent studies. Results: The present review provides a comprehensive and updated overview of the latest evidence about the role of nutrition and diet in pediatric oncology, also focusing on different nutritional interventions available for the management of the disease. We summarize evidence about the importance of adequate nutrition in childhood cancer and the role of several micronutrients and critically interpret the findings. Possible effects and benefits of supplementation during chemotherapy are discussed, as are strategies for primary and secondary prevention. Conclusions: We here describe the obvious benefits of dietary supplementation for childhood cancer. Further large-scale clinical trials are required to verify the impacts of deficiencies and the possible benefits of supplementation and optimal dosages. (337 words).

26 May 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
APAlexandra Podpeskar
Alexandra Podpeskar
RCRoman Crazzolara
Roman Crazzolara
GKGabriele Kropshofer
Gabriele Kropshofer
BHBenjamin Hetzer
Benjamin Hetzer
BMBernhard Meister
Bernhard Meister
CSChristina Salvador
Christina Salvador
Background: Malnutrition is common in children with cancer and is associated with adverse clinical outcomes. The need for supportive care is becoming ever more evident and the role of nutrition in oncology is still not sufficiently understood. In particular, the consequences of macro- and micronutrient deficiencies require further research. As epidemiological data suggest anti-tumoral properties of omega-3 (n-3) polyunsaturated fatty acids (PUFAs), we reviewed the role of nutrition and n-3 supplementation in pediatric oncology. Methods: A comprehensive literature search was conducted on PubMed through 5 February 2021 to select meta-analyses, systematic reviews, observational studies, and individual randomized controlled trials (RCTs) on macro- and micronutrient supplementation in pediatric oncology. The search strategy included the following medical subject headings (MeSH) and keywords: “childhood cancer”, “pediatric oncology”, “nutritional status”, “malnutrition”, and “omega-3-fatty-acids”. The reference lists of all relevant articles were screened to include potentially pertinent studies. Results: We summarize evidence about the importance of adequate nutrition in childhood cancer and the role of n-3 PUFAs and critically interpret findings. Possible effects of supplementation on the nutritional status and benefits during chemotherapy are discussed as well as strategies for primary and secondary prevention. Conclusion: We here describe the obvious benefits of omega-3 supplementation in childhood cancer. Further large scale clinical trials are required to verify potential anti-cancer effects of n-3 fatty acids.